Skip to main content

Table 3 Antihypertensive therapy use at baseline and Week 26

From: Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials

Time point

Placebo

Ertugliflozin 5 mg

Ertugliflozin 15 mg

Patients with one or more antihypertensive therapies

 Baselinea

337 (65.4)

353 (68.0)

336 (65.9)

 Week 26b

316 (66.8)

344 (69.5)

318 (67.5)

RAAS blockers

 Baselinea

292 (56.7)

306 (59.0)

289 (56.7)

 Week 26b

278 (58.8)

298 (60.2)

271 (57.5)

β blockers

   

 Baselinea

120 (23.3)

104 (20.0)

98 (19.2)

 Week 26b

113 (23.9)

101 (20.4)

96 (20.4)

Calcium channel blockers

 Baselinea

94 (18.3)

91 (17.5)

116 (22.7)

 Week 26b

88 (18.6)

93 (18.8)

108 (22.9)

Diuretics

   

 Baselinea

106 (20.6)

112 (21.6)

104 (20.4)

 Week 26b

99 (20.9)

106 (21.4)

98 (20.8)

Other antihypertensive therapy

 Baselinea

22 (4.3)

18 (3.5)

18 (3.5)

 Week 26b

22 (4.7)

18 (3.6)

18 (3.8)

  1. Every patient is counted a single time for each applicable specific medication. A patient with multiple medications within a medication category is counted a single time for that category. Data presented as number of patients (%)
  2. RAAS renin–angiotensin–aldosterone system
  3. aNumber of patients with data: 515 (placebo), 519 (ertugliflozin 5 mg), and 510 (ertugliflozin 15 mg)
  4. bNumber of patients with data: 473 (placebo), 495 (ertugliflozin 5 mg), and 471 (ertugliflozin 15 mg)